Seth Harmon
Vermogen: 138 317 $ op 31-05-2026
Vermogen: 138 317 $ op 31-05-2026
Seth Harmon is currently Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. since 2023.
Formerly, Mr. Harmon was Chief Financial Officer at BioNTech SE from 2020 to 2023 and Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
Mr. Harmon completed undergraduate studies at Bowdoin College and earned graduate degrees, including an MBA, from Northeastern University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 7.850 ( 0,01% ) | 138 317 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Financieel Directeur/CFO | 12-09-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| BIONTECH SE | Financieel Directeur/CFO | 01-05-2023 |
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01-05-2020 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Bowdoin College
Bowdoin College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNTech SE
BioNTech SE BiotechnologyHealth Technology Develops immunotherapies and mRNA-based vaccines to treat cancer & infectious diseases | Health Technology |
BioNTech US, Inc.
BioNTech US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops immunotherapies for cancer | Health Technology |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau